



ClinicalTrials.gov Results Reporting

DATE: January 7, 2016 PRESENTED BY: Lara Fournier and Laura Bradley


Outline

- Introduction
 - Why is this Needed?
 - Does my study require results?
 - Preparing for Results Entry
 - Broad Overview
- Modules
 - Participant Flow
 - Baseline Characteristics
 - Outcome Measures*
 - Adverse Events
- Getting Started with Results Entry
- ClinicalTrials.gov review process
- Overall Tips & FAQs
- Additional Resources

Why Is This Needed?

- Allows greater transparency in research
 - Provide a public record of basic study results in a standardized format
 - Promote the fulfillment of ethical obligations to participants and the overall contribution to medical knowledge
 - Reduces publication and outcome reporting biases
- It's the Law
 - Criminal and/or civil penalties assessed to responsible parties
 - \$10,000 for first event, \$10,000 per day its not corrected within 30 days
 - Notices of Non-compliance
 - Withholding of NIH grant funding

Why is This Needed? It's in the news..



2015 Piller - Law Ignored, Patients at Risk. STAT <http://www.statnews.com/2015/12/13/clinical-trials-investigation/>

Does My Study Require Results Entry?

- If study is an *Applicable Clinical Trial (ACT)*, and thus subject to FDAAA (FDA Amendments Act, Section 801), then IT DOES.
- ACTs are:
 - Controlled clinical investigations involving drugs or prospective studies of health outcomes involving drugs/devices that are subject to FDA regulation (includes IND/IDE)
 - Phase II, III, IV interventional initiated on/after 9/27/2007 or ongoing as of 12/26/2007.
 - Usually* excludes Phase I, Expanded Access studies, pediatric post-market device surveillance.
- *Rules are subject to change so keep checking back to these links:
 - http://grants.nih.gov/clinicaltrials/fdaaa/ACTs_under_FDAAA.htm
 - <https://www.clinicaltrials.gov/ct2/manage-recs/fdaaa>
- *If unsure if your study is ACT, please ask: register@ct.gov or Knight Cancer: ctrp-admin@ohsu.edu}



Preparing for Results Reporting


- **Who enters results?** You! But you can get help.
- **Involve your Biostatisticians** (ideally PI and Biostats should sign-off on final posting), or brush up on statistics.
- **Plan Early!** Ideally -start when you're writing your protocol, to make sure all key elements are reflected in the protocol as well as in your data collection instruments
- Be continuously thinking about your data & results throughout the conduct of your study and update your registration accordingly
- The more accurate, error-free, descriptive and clear your arms/outcomes are in the initial registration, the easier it will be for results reporting
- **Avoid Unpleasant Surprises.** Review the requirements for results entry well ahead of study completion.

Preparing For Results Reporting

- When to Report Results?
 - Within 12 months of **Primary Completion Date** (final data collection for primary outcome(s)).
 - If product is not approved by **Primary Completion Date** but approved later, then results due 30 days after approval.
 - Delays are possible under limited circumstances.
 - Pending publication is NOT considered a good cause for delay
 - Publishing? If you think you can publish within the timeframe, best to prepare both at the same time. Otherwise, post results first, then publish, then update the results in CT.gov so they align.
 - In general, FDAAA requires all primary and secondary outcomes be reported within 12 months of Primary Completion Date
 - In cases where secondary outcome data has not yet completed at that time, report the primary outcome data in the above timeframe, then report the secondary outcome data as soon as available or no later than 12 months after final, study completion date.

Preparing for Results Reporting

- **First Time?** – Check out these links:
 1. How to submit results:
<https://clinicaltrials.gov/ct2/manage-recs/how-report>
 2. Basic Results Data Element Definitions:
https://register.clinicaltrials.gov/prs/html/results_definitions.html
 3. PRS User Guide: Located on the Help menu dropdown, after login
 4. Results Data Entry section on Help Menu dropdown
 5. Webinars and additional training:
<https://clinicaltrials.gov/ct2/manage-recs/present#ResultsPresentation>
- Continue to check for Changes: See **What's New** on the Help Menu dropdown.



Preparing For Results Reporting

- How Are Results Reported in ClinicalTrials.gov?
- Tables are constructed by data providers (you)
 - Rows are measures
 - Columns are Arm / Groups
- 4 broad categories, each with different structure:
 - Participant Flow
 - Baseline Characteristics
 - Outcomes Measures and Statistical Analyses
 - Adverse Events

Module 1: Participant Flow

Definition:

A Table that shows how participants were assigned to intervention(s) and how they progressed through the study.

Arm/Group Title		Remuverol	Placebo
▼ Arm/Group Description		Participants received Remuverol 15 mg tablet orally twice daily for 24 weeks.	Participants received Remuverol placebo tablet (matching Remuverol) orally twice daily for 24 weeks.
Period Title: Overall Study			
Milestone Titles	Started	101	99
	Completed	80	81
	Not Completed	21	18

Module 1: Participant Flow

- Documents the “flow” of participants through different stages of the study
- Should account for all enrolled participants and which were analyzed (or not).
- Elements
 - Recruitment Details (key info related to recruitment process)
 - Pre-assignment Details (details relating to events following enrollment but prior to Arm/Group assignment)
 - Arm/Group (these should pre-populate from your registration)
 - Periods (e.g. “first intervention”, “washout”, “second intervention”), each would be a separate table.
 - Milestones (key events, e.g. “started at least one dose”)
- Overall number “started” should match “Enrollment, Actual” total
- Refer to template:
http://prsinfo.clinicaltrials.gov/results_table_layout/DataEntryTable_PopFlowForm.pdf

Module 1: Participant Flow

- Example 1:
- Study with one period, reports “Overall Study” and one table may be all that’s needed.
- If protocol enrollment and total started don’t match, be sure to add notes

Participant Flow Overview

[Results Section](#) [Help](#) [Definitions](#) [Show All](#)

Protocol Enrollment: 23 [\(edit\)](#)

Total Started in Participant Flow: 19

[Edit](#)

Recruitment Details	Initial recruitment began in Feb 2006 and ended in Dec 2007. 19 patients were put on study during that time frame. These patients came from OHSU oncology clinics or referrals to OHSU.
Pre-Assignment Details	During the first stage, patients not assessable for progression-free status at 3 months due to study discontinuation for any reason except death or progression were replaced only for purposes of determining continuation to the second stage. A total of 19 patients were enrolled in the first stage 15 evaluable patients and 4 patients who were not.

Arm/Group Title	Everolimus and Imatinib Mesylate	Total (Not public)
► Arm/Group Description	Everolimus: 205 mg daily by mouth...	
Period Title: Overall Study		
Started	19 ^[1]	19
Completed	15 ^[2]	15
Not Completed	4	4
<u>Reason Not Completed</u>		
Lack of Efficacy	4	4
(Not Public)		Not Completed = 4 Total from all reasons = 4

[1] 19 patients were enrolled in the first stage due to 4 patients who withdrew early.

[2] 15 patients accrued to the first stage; if >9 were progression-free at 3 months, enrollment continued.

Module 1: Participant Flow

- Example 2:
- Study that is reporting multiple periods

Recruitment Details	This clinical trial was conducted between 12/23/2008 to 3/27/2013 at Oregon Health and Science University's (OHSU) Center for Women's Health Breast Center in Portland, OR. English-speaking women were recruited to participate in the study based on the following inclusion criteria: ≥ 21 years, diagnostic mammogram with results that require biopsy.		
Pre-Assignment Details			
Arm/Group Title	Sulforaphane Supplement	Placebo	Total (Not public)
► Arm/Group Description	Patients receive oral broccoli spro...	Patients receive oral placebo supp...	
Period Title: Treatment Period			
Started	27	27	54
Completed	24	19	43
Not Completed	3	8	11
<u>Reason Not Completed</u>			
Adverse Event	1	5	6
Withdrawal by Subject	2	3	5
(Not Public)	Not Completed = 3 Total from all reasons = 3	Not Completed = 8 Total from all reasons = 8	
Period Title: Follow-up			
Started	24	24	48
		NOTE : The number of participants to start a Period is not equal to the number who completed previous Period.	
Completed Final Visit	24	24	48
Completed	24	24	48
Not Completed	0	0	0

Module 2: Baseline Characteristics

Definition:
Baseline Characteristics is a table of demographic and baseline data, similar to *Table 1* in a journal article

Arm/Group Title	Remuverol	Placebo	Total
► Arm/Group Description	Participants received Remuverol 15 ...	Participants received Remuverol pla...	
Overall Number of Baseline Participants	101	99	200
► Baseline Analysis Population Description			
Age Continuous units: years			
Mean (Standard Deviation)	34.78 (9.72)	35.34 (10.71)	34.98 (9.89)
Gender, Male/Female units: participants Measure Type: Number			
Female	60	63	123
Male	41	36	77

Module 2: Baseline Characteristics

- Elements:
 - Demographic and baseline data for each Arm or Group
 - Accommodates different data types
 - Continuous: measure of central tendency (e.g. mean) and measure of dispersion (e.g., standard deviation)
 - Categorical: for each category – 1) a count OR 2) measure of central tendency and measure of dispersion.
 - Default (Age, Race, Gender)
 - Study-Specific/User Defined (smoking, viral load, etc) – choose what's applicable to the study
- Refer to templates:
http://prsinfo.clinicaltrials.gov/results_table_layout/DataEntryTable_BaselineRegionRaceEthnicityForm.pdf

Module 2: Baseline Characteristics

- Example:
- To add another measure, click Add Baseline Measure

Baseline Measures Overview		
Results Section	Add Baseline Measure	Help Definitions Show All
Edit	Arm/Group Title ▶ Arm/Group Description	Transdermal Estradiol and Paclitaxel Poliglumex NOTE : An entry in Arm/Group Description is recommended.
Edit	Overall Number of Baseline Participants ▶ Baseline Analysis Population Description	21
Edit Delete	Age, Categorical Measure Type: Number Units: participants	
	<=18 years	0
	Between 18 and 65 years	4
	>=65 years	17
Edit Delete	Age, Continuous Mean (Standard Deviation) Units: years	70 (7.6)
Edit Delete	Gender, Male/Female Measure Type: Number Units: participants	
	Female	0
	Male	21
Edit Delete	Region of Enrollment Measure Type: Number Units: participants	
	United States	21

Module 2: Baseline Characteristics

Add Baseline Measure cont.

- 1. Select the type (see link examples)
- 2. Enter details and Save

1.

[Help](#) [Definitions](#)

Study-Specific Measure [Example](#)

Age, Continuous [Example](#)

Age, Categorical [Example](#)

Age, Customized [Example](#)

Gender, Male/Female [Example](#)

Gender, Customized [Example](#)

Race (NIH/OMB) [Example](#)

Ethnicity (NIH/OMB) [Example](#)

Race/Ethnicity, Customized [Example](#)

Region of Enrollment [Example](#)

[Cancel](#)

2.

Edit Baseline Measure

[Help](#) [Definitions](#)

* Study-Specific Baseline Measure Title:

Baseline Measure Description: [Edit](#) Additional information about the measure (e.g., description of scale)
Subjects who were regular smokers (at least one cigarette per day)

Overall Number of Baseline Participants:

* Measure Type:

* Measure of Dispersion:

* Category

Title Number
[Delete](#)

* Category

Title Number
[Delete](#)

* Category

Title Number
[Delete](#)

Total (Not public): 21

[+ Add Category](#)

* Unit of Measure:
Commonly reported units:

[Save](#) [Validate](#) [Cancel](#)

Module 3: Outcome Measures & Statistical Analyses

Definition:

The Outcome Measures module summarizes outcome data using a structured tabular format and for applicable clinical trials includes all pre-specified primary and secondary outcomes. Displays the results and associated analyses.

1. Primary Outcome

Title: Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24

▼ Description: SPS-11 is a validated, self-reported instrument assessing average pain intensity over the past 24 hour period. Possible scores range from 0 (no pain) to 10 (worst possible pain). Change = (Week 24 Score - Baseline score)

Time Frame: Baseline to Week 24

Safety Issue? No

▼ Outcome Measure Data ✓

▼ Analysis Population Description
Intent to treat population (all participants who received at least one dose of intervention). Last observation carried forward (LOCF) imputation method.

Arm/Group Title	Remuverol	Placebo
▼ Arm/Group Description: Participants received Remuverol 15 mg tablet orally twice daily for 24 weeks.	Participants received Remuverol 15 mg tablet orally twice daily for 24 weeks.	Participants received Remuverol placebo tablet orally twice daily for 24 weeks.
Number of Participants Analyzed	101	99
Mean (Standard Error) Units: units on a scale	-3.84 (0.61)	-2.08 (0.51)

Edit ▼ Statistical Analysis 1 ✓

Details

Statistical Analysis Overview	Comparison Groups	Remuverol, Placebo
	Comments	It was calculated that 200 participants randomized in a 1:1 fashion between the 2 arms would have at least 85% power to detect a difference of 0.56 points in mean SPS-11 pain score between Remuverol and placebo from baseline to week 24. Sample size was determined using a 2-sided 2-sample t test ($\alpha = 0.05$). Assumptions included a common standard deviation of 1.14 and a discontinuation rate of 7%.
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	0.002
	Comments	[Not specified]
	Method	Mixed Models Analysis
	Comments	[Not specified]

Module 3: Outcome Measures & Statistical Analyses

- Elements
 - Measure Type (Primary, Secondary, Other)
 - Tables with Arms/Groups & Number of participants analyzed
 - Descriptive Information
 - Title*
 - Description*
 - Unit of Measure*
 - Outcome Measure Time Frame*
 - Reporting Status
 - Safety Issue*
 - Measure Type
 - Measure of Dispersion/Precision (e.g. Standard Deviation)
 - Data
- *Some data will auto-populate from your registration (titles, descriptions, timeframes, etc).*
- Refer to template: http://prsinfo.clinicaltrials.gov/results_table_layout/DataEntryTable_OMForm.pdf

Module 3: Outcome Measures & Statistical Analyses

Primary Outcome Measure:



Outcome 1

* Title: Dysphagia Questionnaire

* Time Frame: At the end of the study

Description:

(†) Safety Issue? No

× Delete Outcome

Primary Outcome Measure:



Outcome 1

* Title: Number of Patients with Complete Response to Dysphagia

* Time Frame: Baseline to 6 weeks


Description:

(†) Safety Issue? No

× Delete Outcome

Module 3: Outcome Measures & Statistical Analyses

- Example
- Journal articles have similar information, just presented in different format
- To edit outcome, click Edit next to listed outcome



Outcome Measures Overview

[Results Section](#) [Add Outcome Measure](#) [Reorder Outcome Measures](#) [Help](#) [Definitions](#) [Show All](#)

[Edit](#) [Delete](#) [Copy](#)

1. Primary Outcome

Title:	PSA Response Rate
▼ Description:	PSA response rate is defined at the number of patients who experienced a PSA decline of equal to or greater than 50%, confirmed by a second measurement at least 4 weeks later.
Time Frame:	While receiving study agents
Safety Issue?	No

▼ Outcome Measure Data ✓ 1 Note

▼ Analysis Population Description

[Not specified]

Arm/Group Title	Transdermal Estradiol and Paclitaxel Poliglumex
▼ Arm/Group Description:	[Not specified]
	NOTE : An entry in Arm/Group Description is recommended.
Number of Participants Analyzed	21
Measure Type: Number Units: Participants	0

[Add Statistical Analysis 1](#)

[Edit](#) [Delete](#) [Copy](#)

2. Secondary Outcome

Title:	Measurable Disease Response Rate
► Description:	Measurable disease response rate by RECIST criteria.
Time Frame:	While on study regimen
Safety Issue?	No

Module 3: Outcome Measures & Statistical Analyses

Edit Outcome cont.

1. Make sure all * (required) fields are filled out
2. Completing optional description fields is recommended.
3. Select Measure Type
4. Measure of Dispersion
5. Enter Data
6. Select Units

Time Frame: while receiving study agents

(+) Safety Issue? No

Arms/Groups (1) + Add Arm/Group

Arm/Group Title: **Transdermal Estradiol and paclitaxel poliglumex**

Arm/Group Description: NOTE : An entry in Arm/Group Description is recommended.

* Number of Participants Analyzed: 21

+ Add Units Analyzed (Optional) Use only if analysis is based on units other than participants (e.g., eyes, lesions, implants).

Analysis Population Description: Characters remaining: 350

Outcome Measure Data Table

* Measure Type: Mean

* Measure of Dispersion/Precision: 90% Confidence Interval

Transdermal Estradiol and paclitaxel poliglumex

Mean: 20

90% Confidence Interval: 15 to 20

+ Add Category

* Unit of Measure: Participants

Commonly reported units: participants | years | units on a scale | percentage of <something>

Module 3: Outcome Measures & Statistical Analyses

- To Add a Statistical Analysis, Click Add Statistical Analysis

Outcome Measures Overview
[Results Section](#) [Add Outcome Measure](#) [Reorder Outcome Measures](#) [Help](#) [Definitions](#) [Show All](#)

[Edit](#)
[Delete](#)
[Copy](#)

1. Primary Outcome

Title:	PSA Response Rate
▼ Description:	PSA response rate is defined as the number of patients who experienced a PSA decline of equal to or greater than 50%, confirmed by a second measurement at least 4 weeks later.
Time Frame:	While receiving study agents
Safety Issue?	No
▼ Outcome Measure Data ✓ 1 Note	
▼ Analysis Population Description [Not specified]	
Arm/Group Title	Transdermal Estradiol and Paclitaxel Poliglumex
▼ Arm/Group Description:	[Not specified] NOTE : An entry in Arm/Group Description is recommended.
Number of Participants Analyzed	21
Measure Type: Number Units: Participants	0

[Add Statistical Analysis 1](#)

[Edit](#)
[Delete](#)
[Copy](#)

2. Secondary Outcome

Title:	Measurable Disease Response Rate
► Description:	Measurable disease response rate by RECIST criteria.
Time Frame:	While on study regimen
Safety Issue?	No

Module 3: Outcome Measures & Statistical Analyses

- Statistical Analysis cont.
 1. Select the outcome Arm/Group you are adding the analysis for
 2. Add Non-inferiority or Equivalence Analysis
 3. Statistical Test of Hypothesis
 4. Method (ANOVA, Wilcoxon, etc.)

Add Outcome Statistical Analysis	
Primary Outcome	
Title:	PSA response rate
Time Frame:	While receiving study agents
Unit of Measure:	Participants

Tip: Many of the data elements are optional and may be left blank. The minimum requirements are to enter either a P-Value OR an Estimation Parameter (e.g., Mean Difference, Odds Ratio). A Confidence Interval for the Estimation Parameter may also be entered.

Statistical Analysis Overview

[Help](#) [Definitions](#)

* Comparison Group Selection:	Select the Outcome Measure Arms/Groups involved in the statistical analysis. <input type="checkbox"/> Transdermal Estradiol and paclitaxel poliglumex
Comments:	(Optional) Additional details about the statistical analysis, such as null hypothesis and description of power calculation. <div>Characters remaining: 500</div>
* Non-inferiority or Equivalence Analysis?	<input type="checkbox"/> Yes
Comments:	If "Yes" (non-inferiority or equivalence analysis), describe details of the power calculation (if not previously provided), definition of non-inferiority margin, and other key parameters. <div>Characters remaining: 500</div>

Statistical Test of Hypothesis

[Help](#) [Definitions](#)

P-Value:	(If applicable) <input type="text" value="0.02"/> (e.g., <0.01)
----------	--

Module 3: Outcome Measures & Statistical Analyses

- Statistical Analysis cont.
 6. Adding comments for greater clarity is encouraged
 7. Enter method of estimation details
 8. Hit Save

Method: (Required if a P-Value is entered)
ANOVA If other, please specify:

Comments: (Optional) Any other relevant information, such as adjustments or degrees of freedom.

Characters remaining: 150

Method of Estimation
[Help](#) [Definitions](#)

Estimation Parameter: (If applicable)
Mean Difference (Final Values) If other, please specify:

Estimated Value: Provide the data for the Estimation Parameter.

Confidence Interval: (If applicable) % Confidence Interval
Number of sides: 2-Sided
Lower Limit:
Upper Limit:

Parameter Dispersion Type and Dispersion Value: (If applicable)
Standard Deviation

Estimation Comments: (Optional) Any other relevant estimation information, including the direction of the comparison (e.g., describe which arm or comparison group represents the numerator and denominator for relative risk).

Characters remaining: 250

Module 3: Outcome Measures & Statistical Analyses

Statistical Analysis cont.

- Example

Measure Type	Primary
Measure Title	Invasive Breast Cancer Incidence (Breast Cancer-Free Survival)
Measure Description	Invasive breast cancer incidence was estimated from the breast cancer-free survival (BCFS) which was calculated for all women from the day of the randomization to the earliest date of diagnosis for invasive breast cancer. Women who died from other causes were censored at the time of death. If a woman did not develop an invasive breast cancer, or died, BCFS was censored on the date of the last day the woman was known alive (LKA), which was the latest of the date of assessment. Women who had breast cancer before study entry were also censored at the time of randomization.
Time Frame	Over study (median follow-up 35 months)
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

intention to treat (ITT)

Reporting Groups

	Description
Exemestane	25 mg of exemestane tablet daily
Placebo	Placebo tablet daily

Measured Values

	Exemestane	Placebo
Number of Participants Analyzed [units: participants]	2285	2275
Invasive Breast Cancer Incidence (Breast Cancer-Free Survival) [units: percentage of cases/follow-up person-yr] Number (95% Confidence Interval)	0.19 (0.08 to 0.30)	0.55 (0.36 to 0.73)

Statistical Analysis 1 for Invasive Breast Cancer Incidence (Breast Cancer-Free Survival)

Groups ^[1]	All groups
Method ^[2]	Log Rank
P Value ^[3]	0.002
Hazard Ratio (HR) ^[4]	0.35
95% Confidence Interval	0.18 to 0.70

Module 4: Adverse Events

Definition:

“Unfavorable changes in health, including abnormal laboratory findings that occur in trial participants during the clinical trial or within a specified period following the trial.”

Edit	Time Frame		
	Additional Description		
	Source Vocabulary Name	MedDRA (12.0)	
	Assessment Type	Systematic Assessment	
Edit	Arm/Group Title	Remuverol	Placebo
	▼ Arm/Group Description	Participants received Remuverol 15 mg tablet orally twice daily for 24 weeks.	Participants received Remuverol placebo tablet orally twice daily for 24 weeks.
▼ Serious Adverse Events			
		Remuverol Affected / at Risk (%)	Placebo Affected / at Risk (%)
Edit	Total	4/101 (3.96%)	0/99 (0%)
Edit	Blood and l... Anemia Iron Deficiency †	1/101 (0.99%)	0/99 (0%)
	Immune syst... Viral Meningitis †	1/101 (0.99%)	0/99 (0%)
	Skin and su... Psoriasis †	1/101 (0.99%)	0/99 (0%)
	Blood and l... Idiopathic Thrombocytopenic Purpura †	1/101 (0.99%)	0/99 (0%)
† Indicates events were collected by systematic assessment.			
Add Serious Adverse Event			
▼ Other (Not Including Serious) Adverse Events			
Edit	Frequency Threshold for Reporting Other Adverse Events	1%	
		Remuverol Affected / at Risk (%)	Placebo Affected / at Risk (%)
Edit	Total	98/101 (97.03%)	46/99 (46.46%)
Edit	Ear and lab... Earache †	35/101 (34.65%)	7/99 (7.07%)
	Endocrine d... Hypothyroidism †	27/101 (26.73%)	25/99 (25.25%)
	Eye disorde... Conjunctivitis †	13/101 (12.87%)	4/99 (4.04%)
	Gastrointes... Nausea †	12/101 (11.88%)	7/99 (7.07%)
	Gastrointes... Stomachache †	10/101 (9.9%)	2/99 (2.02%)
	Gastrointes... Vomiting †	10/101 (9.9%)	3/99 (3.03%)
† Indicates events were collected by systematic assessment.			
Add Other (Not Including Serious) Adverse Event			

Module 4: Adverse Events

- Elements:
 - Module consists of two tables of summary adverse event data for each Arm/Group.
 - Serious Adverse Events (SAEs)
 - Includes a table of ALL anticipated and unanticipated SAEs grouped by organ system, with number and frequency of such events per Arm/Group
 - Other Adverse Events
 - Includes a table of anticipated and unanticipated adverse events that exceed 5 % frequency within an Arm/Group.
- Refer to templates:
 - http://prsinfo.clinicaltrials.gov/results_table_layout/DataEntryTable_SAEForm.pdf
 - http://prsinfo.clinicaltrials.gov/results_table_layout/DataEntryTable_FreqAEForm.pdf
- You can enter manually or download, then upload a template.

Module 4: Adverse Events

Example:

Data is compiled by organ system then:

- Number of subjects affected*
- Number subjects at risk* (*number that received the intervention*)
- Number of events (optional)

Adverse Events Overview

Results SectionDownload/UploadSort...HelpDefinitionsShow All

Edit

Time Frame

Additional Description

Source Vocabulary Name

Assessment Type

While on study agents

CTCAE (3.0)

[Not specified]

NOTE : An Assessment Type for Table Default has not been specified.

Edit

Arm/Group Title

Arm/Group Description

Transdermal Estradiol and Paclitaxel Poliglumex

NOTE : An entry in Arm/Group Description is recommended.

Serious Adverse Events

Edit

Transdermal Estradiol and Paclitaxel Poliglumex

Affected / at Risk (%)

Events

Total

3/21 (14.29%)

Gastrointes...

Gastric Hemorrhage [1] A

1/21 (4.76%)

1

Respiratory...

Pneumonitis [2] B

1/21 (4.76%)

1

Gastrointes...

Nausea and Vomiting [3] B

1/21 (4.76%)

1

A

Term from vocabulary, CTCAE v. 3.0

B

Term from vocabulary, CTCAE (3.0)

[1]

Subject admitted for gastric hemorrhage and thrombocytopenia. Event determined to be possibly related to study agents.

[2]

Subject admitted with lethargy, cough and elevated temperature. Chest X-ray demonstrated pneumonitis. Event determined to be possibly related to study agents.

[3]

Subject admitted for intractable nausea and vomiting. Abdominal ultrasound was normal. Event deemed possibly related to study agents

Add Serious Adverse Event

Other (Not Including Serious) Adverse Events

Edit

Frequency Threshold for Reporting Other Adverse Events

5%

Transdermal Estradiol and Paclitaxel Poliglumex

Affected / at Risk (%)

Events

Total

20/21 (95.24%)

Blood and l...

hemoglobin decreased ^

9/21 (42.86%)

Blood and l...

Leukopenia ^

3/21 (14.29%)

Blood and l...

Lymphopenia ^

6/21 (28.57%)

Blood and l...

Thrombocytopenia ^

4/21 (19.05%)

General dis...

Fatigue ^

6/21 (28.57%)

Skin and su...

Rash ^

3/21 (14.29%)

Gastrointes...

Anorexia ^

4/21 (19.05%)

Gastrointes...

Constipation ^

5/21 (23.81%)

Gastrointes...

Diarrhea ^

4/21 (19.05%)

Gastrointes...

Nausea ^

4/21 (19.05%)

Module 4: Adverse Events

Download/
Upload Option –
a likely time
saver.

1. Click
Download
/Upload
2. Download
Excel
template
and fill out
3. Click upload

The screenshot shows the 'Adverse Events Overview' page on ClinicalTrials.gov. The page title is 'ClinicalTrials.gov PRS Protocol Registration and Results System'. The breadcrumb trail is 'Home > Record Summary > Results Section > Adverse Events'. The ID is 'CDR00005404' and the study is 'Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer'. The 'Results Section' tab is selected, and the 'Download/Upload' link is highlighted with a blue arrow and the number '1'. Below the tabs, there is an 'Edit' link and a 'Time Frame' dropdown set to 'While on study agents'. A large orange arrow points from the 'Download/Upload' link to the 'Download Adverse Event Tables from PRS' section, which is annotated with the number '2'. This section has two radio buttons for 'Adverse Event Type' (Serious, Other (Not Including Serious)) and two radio buttons for 'File Format' (Excel Workbook (.xlsx), Excel 97-2003 Workbook (.xls)). A green 'Download' button is present. Below this is the 'Upload Adverse Events to PRS' section, annotated with the number '3'. It has a 'Filename' field with a 'Browse...' button, the same 'Adverse Event Type' and 'File Format' options, and a 'Worksheet Name' field. A green 'Upload' button is circled in red.

Download Adverse Event Tables from PRS

* Adverse Event Type: ☐ Serious ☐ Other (Not Including Serious)

* File Format: ☐ Excel Workbook (.xlsx) ☐ Excel 97-2003 Workbook (.xls)

Download

Upload Adverse Events to PRS

* Filename: Browse... No file selected.

* Adverse Event Type: ☐ Serious ☐ Other (Not Including Serious)


* File Format: ☐ Excel Workbook (.xlsx) ☐ Excel 97-2003 Workbook (.xls) ☐ Tab Separated Values (.txt)

For multi-sheet Excel workbooks only, Worksheet Name:

Upload

Getting Started with Results Entry

- When ready to start...
 1. Login to PRS and navigate to your protocol registration
 2. Click **Enter Results**
 - This will set up the full outline of the Results Section for you (next screen)



ClinicalTrials.gov PRS: Record Summary NCT00053248 - Windows Internet Explorer provided by OHSU

https://prtest.nlm.nih.gov/prs/app/action/SelectProtocol?sid=500007NM&selectaction=Edit&uid=U0000W56&ts=11&cx=e57n6o

Suggested Sites CDE Browser Google CRI SPOC Knight Box MyActive

ID: CDR0000269319 Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia NCT00053248

[Opening](#) [Preview](#) [Draft Receipt \(PDF\)](#) [Download XML](#) [Admin Only](#) [Copy Protocol](#) [Change Owner](#)

[Open](#) **Protocol Section**

Identifiers: NCT00053248 Unique Protocol ID: CDR0000269319 Secondary IDs: OHSU-UCLA-0206062, OHSU-HEM-02001-L, OHSU-1096

Brief Title: Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Module Status:

- Study Identification: ✓ 4 Notes
- Study Status: ✓
- Sponsor/Collaborators: ✓ 2 Notes
- Oversight: ✓
- Study Description: ✓
- Conditions: ✓ 1 Note
- Study Design: ✓ 2 Notes
- Arms and Interventions: ✓ 5 Notes
- Outcome Measures: ✓ 4 Notes
- Eligibility: ✓ 1 Note
- Contacts/Locations: ✓
- References: ✓

Results Section

[Enter Results](#) Results submission is required by FDAAA 801 for certain [applicable clinical trials](#) of drugs, biologics and devices. Note: other clinical trials may need to have results submitted based on other funder or sponsor policies.

[Start Results data entry](#)

[Delay Results](#) For applicable clinical trials subject to FDAAA 801, results submission may be delayed (in limited circumstances) with a Certification or Extension Request.


For more information see: [When Do I Need to Register and Submit Results?](#)

[Add](#) **Record Log**

https://prtest.nlm.nih.gov/prs/rs/ConfirmCreateResult?uid=U0000W56&ts=12&sid=500007NM&...

Getting Started with Results Entry

- Getting started cont.
 3. Click **Edit** to begin entry on the 4 modules
 4. When complete with all 4 modules, make sure to complete **Limitations and Caveats** (if applicable), and **Agreements & Contacts**
 5. Completing the Limitations section will be *important if there are issues with your results data* (incomplete data, terminated early, etc)



The screenshot displays the 'Results Section' interface. At the top, there are navigation links: 'Record Summary' (active), 'Preview Results', 'Download Results XML', 'Delete Results', and 'Help'. Below these, several modules are listed, each with an action link and a status message:


- Participant Flow**: Action link 'Edit', status 'Information is required'.
- Baseline Characteristics**: Action link 'Edit', status 'Information is required'.
- Outcome Measures**: Action link 'Open', status 'Information is required'.
- Adverse Events**: Action link 'Edit', status 'Information is required'.
- Limitations and Caveats**: Action link 'Edit', status '[Not Specified]'.
- More Information**: Action link 'Open', containing two sub-sections:
 - Certain Agreements**: Status '[Relationship of Principal Investigator and Sponsor not specified.]', 'Information is required'.
 - Results Point of Contact**: Fields for Name/Official Title, Organization, Phone, and Email, all marked '---', with a status 'Information is required'.

An orange arrow points from the text 'Limitations and Caveats' in the list to the 'Limitations and Caveats' module in the interface.

Getting Started with Results Entry

Navigation & Editing Tips

- Be aware, there are lots of nested edit functions & pop-ups
- Take your time, navigation can get confusing
- Don't forget to hit **Save**




Reason Not Completed

Other Reason: 1
Other Reason: Car accident

Not Completed = 1
Total from all reasons = 1

Save **Validate** **Cancel**



Edit Participant Flow

[Help](#) [Definitions](#)

Recruitment Details: **Edit** Twenty-one patients enrolled in the trial between March 2007 and May 2008 in the medical clinics at Oregon Health & Science University and the University of California at San Francisco.

Pre-assignment Details: **Edit**

Arms/Groups (1) **+ Add Arm/Group**

* Arm/Group Title: **Transdermal Estradiol and axel poliglumex**

Arm/Group Description: **NOTE : An entry in Arm/Group Description**

Periods (1)

* Period Title: **Overall Study**

* Started: 21 **Add Comment**

* Completed: 20 **Add Comment**

Not Completed: 1 (Started - Completed)

Reason Not Completed

Other Reason: 1
Other Reason: Car accident

Recruitment Details (Optional)

Definition: Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and types of location (e.g., medical clinic), to provide context.


Characters remaining: 165

Twenty-one patients enrolled in the trial between March 2007 and May 2008 in the medical clinics at Oregon Health & Science University and the University of California at San Francisco.

OK **Cancel**

Getting Started with Results Entry

- When you're all finished with results entry we recommend
 - Have a second person (ideally the PI and/or Biostatistician) review it
 - Mistakes can be embarrassing
 - You can export a RTF or PDF version of the entire registration & results data if they are not comfortable navigating in CT.gov




Spelling Preview Draft Receipt (PDF RTF) Download XML Admin Only: Copy Protocol Change Owner

Open Protocol Section

Identifiers: NCT00370009 Unique Protocol ID: CDR0000479150 Secondary IDs: OHSU-SOL-05108-LM, FWA00000161, OHSU-1754

Brief Title: Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

- **Complete, Approve then Release** the record and it will then go into PRS Review (QA)




Record Status

In Progress → Entry Completed → **Approved** → Released → PRS Review → Public

[Reset to In-Progress...](#)


Next Step: Release record **Release...**

ClinicalTrials.gov PRS QA Process



ClinicalTrials.gov PRS QA Process

- The QA Process can take a while, especially if it happens multiple times
- The more accurate, complete and specific the results are, the quicker the process will go
- To review the comments, login to PRS and select PRS Review Comments under the Records menu.



ClinicalTrials.gov PRS QA Process

Example 1:

- Measure Types need to be consistent with outcome description

2. Secondary Outcome Measure [Posted]: Second-line Progression Free Survival

Measure Title	Second-line Progression Free Survival
Measure Description	Time to disease progression from start of second-line experimental reg... Evaluation Criteria in Solid Tumors Criteria (RECIST v1... disappearance of all target lesions; Partial Response (P... Progressive Disease (PD), >= 20% increase in the sum... sufficient shrinkage to qualify for partial response nor su...
Time Frame	Upon completion of follow-up, for an average of 99 days
Safety Issue?	No

Analysis Population Description -- Explanation of how the number of participants to treat, or another method. Also provides relevant details such as impact of missing data.

Reporting Groups

	Description
FOLFIRI With Erlotinib	
FOLFOX With Erlotinib	

Validation Messages

- NOTE : An entry in Arm/Group Description is recommended.
- NOTE : An entry in Arm/Group Description is recommended.

2. Secondary Outcome

[Add Statistical Analysis 1](#)

[Edit](#) [Delete](#) [Copy](#)

Title:	Second-line Progression Free Survival	
Description:	Time to disease progression from start of second-line experimental reg...	
Time Frame:	Upon completion of follow-up, for an average of 99 days following the initiation of study treatment.	
Safety Issue?	No	

▼ Outcome Measure Data ✓ 2 Notes

► Analysis Population Description

Arm/Group Title	FOLFIRI With Erlotinib	FOLFOX With Erlotinib
► Arm/Group Description:	NOTE : An entry in Arm/Group Description is recommended.	NOTE : An entry in Arm/Group Description is recommended.
Number of Participants Analyzed	10	1
Median (95% Confidence Interval) Units: Days	83 (15 to 127)	125 (--- to ---)

[Collapse Section](#)

Comments [2] :

It appears that the Measure Type of Number is incorrect. If reporting the average time to progression, then please provide the appropriate Measure Type (e.g., Mean, Median, etc.) and Measure of Dispersion/Precision (e.g., Standard deviation, Full Range, Confidence Interval, etc.). Please review and revise as appropriate.

Revised to

ClinicalTrials.gov PRS QA Process

Example 2 & 3

- Totals should match with enrollment, else explain.
- Outcome title and/or description need to be specific

Comments [1] :

The Enrollment number in the protocol section (60) conflicts with the number of participants Started in the Participant Flow module (46). Please verify and correct either or both of these data elements, or otherwise explain the apparent discrepancy in Pre-Assignment Details, as appropriate.

▼ [hide](#)

Period Title: Overall Study

Arm/Group Title	Sunitinib and Erlotinib	Total (Not public)
Started	46	46
Completed	43	43
Not Completed	3	3

▶ 4. Secondary Outcome: Treatment Compliance

▼ [hide](#)

Title:	Treatment Compliance
▼ Description:	[Not specified]
Time Frame:	Baseline and end of study (up to 8 weeks)
Safety Issue?	No

Comments [1] :

Please consider explicitly indicating the criterion that participants had to meet in order to have been considered "compliant."

▼ Outcome Measure Data

▼ [hide](#)

ClinicalTrials.gov PRS QA Process

Example

4 & 5

- Timeframe need to be specific
- Outcome language should be “neutral”

▶ 1. Primary Outcome: Maximum Tolerated Dose (MTD) of Erlotinib Hydrochloride When Used in Combination With Sunitinib. [hide](#)

Title:	Maximum Tolerated Dose (MTD) of Erlotinib Hydrochloride When Used in Combination With Sunitinib.
▼ Description:	The MTD is defined as the dose that produces dose limiting toxicity (DLT) in 33% of the patients.
Time Frame:	Evaluated at each dose level for the duration of the study.
Safety Issue?	Yes

Comments [2] :

The Time Frame provided is not specific. The Time Frame should specify the specific time point(s) at which the outcome measure was assessed and for which data are presented (e.g., "Evaluated at each dose level for the duration of the study, up to 6 weeks" or similar, as accurate and appropriate).
This issue also applies to the following Outcome Measures.

▼ Outcome Measure

▶ 6. Secondary Outcome: Maximum Percent Reduction in Tumor Measurement [hide](#)

Title:	Maximum Percent Reduction in Tumor Measurement
▼ Description:	The maximum percent reduction in Tumor Measurement is the greatest percent reduction in longest diameter (LD) for the target lesions from the baseline LD. For patients with no reduction in LD, the maximum percent reduction is the lowest increase in LD from the baseline LD.
Time Frame:	Baseline through end of study
Safety Issue?	No

Comments [3] :

In general, the preferred format is to use "outcome-neutral" language in Outcome Measure Titles and Descriptions (e.g., "percent change" instead of "percent reduction"). This is particularly important for outcome data with a negative value as it may not be obvious to a reader how to interpret a "reduction" that is "negative". Please review, and, if possible, use outcome-neutral language throughout the measure, with positive numbers to represent increases and negative numbers to represent decreases.

ClinicalTrials.gov PRS QA Process

Example 6

- What if I don't have the data?
 - Studies that terminated early – can enter '0s'
 - Or – apply for an extension if you think you will get the data
- Better to post what you have by due date, than be late.

2. Secondary Outcome Measure [Not Posted]: Time to PSA Recurrence as Seen by 2 Measurements Performed a Week Apart [Collapse Section](#)

Measure Title	Time to PSA Recurrence as Seen by 2 Measurements Performed a Week Apart
Measure Description	Due to the limited enrollment, this analysis was not completed.
Time Frame	Measured at time of PSA recurrence
Safety Issue?	No

Data Not Posted
Anticipated Posting Date:

Validation Messages
🔔 NOTE : A Measure Description is shorter than the Measure Title.

Comments:

Will data be posted in the future? If not:
"0s" can be included for Number of Participants Analyzed and the value fields can be left blank. Please still post the Outcome Measure and include the Measure Title, Description, Time Frame, Measure Type, Measure of Dispersion, and Unit of Measure, etc., as appropriate. Further clarification should be provided in the Analysis Population Description fields and, if appropriate, in the Limitations and Caveats Module.
The Time Frame provided is not specific. The Time Frame should specify the specific time point(s) at which the outcome measure was assessed and for which data are presented. For example, "1 year" or "up to 24 weeks." An average time period may also be acceptable (e.g., if participants were followed until death), but the time frame should specify that it is an average.
Some or all of the issues noted for this Measure also apply to other Measures. Please review and correct as necessary.

Overall Tips & FAQs

- Remember to hit **Save** to your work, or **Cancel** if you don't want to Save
- Publications can be more detailed and expansive than posted results but they should be consistent & congruent. If publishing *after* posting results, go back and update results to ensure they are consistent
- Make sure units and scales are labeled and understandable
- Outcome titles, avoid using verbs (e.g. "To determine...")
– focus on what is measured and not why
- You are not required to address all auto-generated "Notes" before submitting your results, however, warnings and errors should be addressed
- Make sure acronyms are spelled out first time they are used

References and Additional Resources

- Clinicaltrials.gov information general results info: <https://www.clinicaltrials.gov/ct2/about-site/results>
- Clinicaltrials.gov information detailed results info: <https://clinicaltrials.gov/ct2/manage-recs/how-report>
- Questions?
 - ClinicalTrials.gov staff - register@clinicaltrials.gov
 - Oncology/Cancer Studies (Knight Cancer Institute) - ctrp-admin@ohsu.edu
 - Non-cancer - OCTRI {Contact??}
- FDAAA & Elaborations of Definitions: <https://www.clinicaltrials.gov/ct2/manage-recs/fdaaa>
- CMS – Mandatory Reporting of NCT #s on Medicare Claims Q&A
<https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/Downloads/Mandatory-Clinical-Trial-Identifier-Number-QsAs.pdf>
- PRS User's Guide XML section (must be logged in to PRS to access)
<https://register.clinicaltrials.gov/prs/app/template/ReferenceGuide.vm?popup=true&uid=U0000W56&ts=3&cx=-pf1azb#xml>
- OHSU Knight Clinical Trial Registration SOPs: CR007, CR013 -
<https://bridge.ohsu.edu/research/knight/policies/SitePages/Home.aspx>
- Knight CTRP staff ctrp-admin@ohsu.edu
- OHSU ClinicalTrials.gov IRB Help Sheet:
<http://www.ohsu.edu/xd/about/services/integrity/policies/upload/Clinical-Trials-ClinicalTrials-gov-Registration-Requirements-Help-Sheet.pdf>

Some of the slides were adapted with permission from the work of the Clinical and Translational Science Awards (CTSA) program's Clinical Trials Registration Workgroup of the Regulatory Knowledge Key Function Committee. Original slides available at Harvard Catalyst
<https://catalyst.harvard.edu/programs/regulatory/clinical-trial-reg.html>

The Clinical and Translational Science Awards Program (CTSA) is part of the Roadmap Initiative, Re-Engineering the Clinical Research Enterprise and is funded by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH).



Thank You